TMOON
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Vardas TMOON
Reitingas No.3553
Rinkos kapitalizacija $0.00
Visiškai sumažinta rinkos kapitalizacija $0.00
Rinkos dalis %
Prekybos apimtis / rinkos kapitalizacija (24 val.) 6,113,088.93%
Cirkuliuojantis kiekis 10.68300219
Maksimali pasiūla 0
Bendra pasiūla 10.68300219
Cirkuliacijos norma %
Išleidimo data --
Kaina, už kurią turtas buvo išleistas pirmą kartą --
Visų laikų rekordas 643.187233444486, 2026-01-22
Mažiausia kaina 437.1989421522778, 2026-05-18
Vieša blokų grandinė TMOON
Įvadas Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Sektorius
Socialinė žiniasklaida
Fondo srautų analizė
|
Pirkti(TMOON) |
Parduoti(TMOON) |
Grynasis srautas |
| Didelis |
0.000 |
0.000 |
0.000 |
| Vidutinis |
0.000 |
0.000 |
0.000 |
| Mažas |
23.935 |
12.489 |
11.445 |
| Iš viso |
23.935 |
12.489 |
11.445 |
etfindex:mc_etfindex_source Atsisakymas: cmc pateikti duomenys ir neturėtų būti laikomi investavimo patarimais.
